The acute coronary syndrome market is experiencing significant growth, driven by the increasing prevalence of both acute ...

Despite the recommendation for in-hospital initiation of high-intensity statin therapy in AIS patients, achieving the desired target LDL-C levels remains challenging. Evolocumab, a highly effective ...

The acute coronary syndrome market is experiencing significant growth, driven by the increasing prevalence of both acute myocardial infarction (AMI) and unstable angina, an aging global population ...

For patients with severe elevations in low-density lipoprotein (LDL) cholesterol (≥190 mg/dL) and a combination of clinical ...

These drugs reduce the cholesterol your body makes and help clear out LDL in your blood vessels where they can leave ...

Company provided an update on the obicetrapib clinical development program and outlined its strategic priorities for ...

Pharmaceuticals, including non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen (IBU) and naproxen (NPX), are widely used for medical purposes but have also become prevalent environmental ...

There is an increasing incidence of young breast cancer (YBC) patients with uncertainty surrounding the factors and patterns that are contributing.We obtained characteristics and survival data from ...

Repatha (evolocumab) will be sold in the UK at a cost of $6,780 per year, less than half the $14,100 Amgen is charging for the drug in the US, with the price in other EU markets typically below ...

Additional data from BROADWAY, BROOKLYN, and TANDEM to be presented throughout 2025; expected to support global regulatory filings for ...

These drugs work by targeting a protein that prevents the body from clearing LDL cholesterol (the “bad” cholesterol) from the ...

Pfizer is in a three-way fight to bring the first PCSK9 inhibitor to market with Amgen and Sanofi/Regeneron whose respective evolocumab and alirocumab candidates have already been filed for ...